Fallopian Tube Endometrioid Tumor: Clinical Trials

2 trials for Fallopian Tube Endometrioid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Completed 1

Follow Fallopian Tube Endometrioid Tumor: new trials by email Literature Review of Fallopian Tube Endometrioid Tumor trials Research Report on Fallopian Tube Endometrioid Tumor

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)612019-12-042026-08-26
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Laboratory Biomarker Analysis, Monitoring Device, Physical Activity - Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm
Phase 2CompletedRoswell Park Cancer Institute92017-06-272021-09-02

Narrower conditions

Fallopian Tube Neoplasms (2)  ·  Ovarian Neoplasms (1)

Broader conditions

Adnexal Diseases (2)  ·  Fallopian Tube Diseases (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genital Diseases (2)  ·  Genital Diseases, Female (2)  ·  Genital Neoplasms, Female (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Gonadal Disorders (1)  ·  Ovarian Diseases (1)

Interventions

Exercise (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Monitoring, Physiologic (1)  ·  Specimen Handling (1)  ·  olaparib (1)  ·  tremelimumab (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (2)

Top investigators

Emese Zsiros (1)  ·  Sarah F Adams (1)

NIH funding

U10CA180868 (1)